Trial Outcomes & Findings for Tremelimumab With Chemoembolization or Ablation for Liver Cancer (NCT NCT01853618)
NCT ID: NCT01853618
Last Updated: 2019-12-10
Results Overview
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
61 participants
Primary outcome timeframe
Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1; 49 months and 26 days for 2/Arm A2; 1 month and 26 days for 3/Arm B; 30 months and 20 days for 5/Arm D; and 34 months and 25 days for 6/Arm E.
Results posted on
2019-12-10
Participant Flow
4/Arm C never opened, thus no participants were enrolled in this group.
Participant milestones
| Measure |
3/Arm B - Tremelimumab + TACE
Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 3.5 mg/kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
2/Arm A2 - Tremelimumab + RFA or TACE
Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
5/Arm D - Tremelimumab + Cryoablation
Tremelimumab + Cryoablation
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Cryoablation: Performed on Day 36
|
6/Arm E - Tremelimumab + RFA
Tremelimumab + Radiofrequency Ablation (RFA)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
12
|
8
|
12
|
9
|
20
|
|
Overall Study
COMPLETED
|
10
|
6
|
10
|
8
|
17
|
|
Overall Study
NOT COMPLETED
|
2
|
2
|
2
|
1
|
3
|
Reasons for withdrawal
| Measure |
3/Arm B - Tremelimumab + TACE
Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 3.5 mg/kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
2/Arm A2 - Tremelimumab + RFA or TACE
Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
5/Arm D - Tremelimumab + Cryoablation
Tremelimumab + Cryoablation
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Cryoablation: Performed on Day 36
|
6/Arm E - Tremelimumab + RFA
Tremelimumab + Radiofrequency Ablation (RFA)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
|
|---|---|---|---|---|---|
|
Overall Study
Bile duct stent blockage/progressive dis
|
0
|
1
|
0
|
0
|
0
|
|
Overall Study
Progressive disease
|
1
|
1
|
1
|
1
|
2
|
|
Overall Study
Physician Decision
|
1
|
0
|
1
|
0
|
0
|
|
Overall Study
Refused further treatment
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Baseline characteristics by cohort
| Measure |
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
n=8 Participants
Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 3.5 mg/kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
2/Arm A2 - Tremelimumab + RFA or TACE
n=12 Participants
Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
3/Arm B - Tremelimumab + TACE
n=12 Participants
Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
5/Arm D - Tremelimumab + Cryoablation
n=9 Participants
Tremelimumab + Cryoablation
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Cryoablation: Performed on Day 36
|
6/Arm E - Tremelimumab + RFA
n=20 Participants
Tremelimumab + Radiofrequency Ablation (RFA)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
|
Total
n=61 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
6 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
18 Participants
n=21 Participants
|
48 Participants
n=8 Participants
|
|
Age, Categorical
>=65 years
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
13 Participants
n=8 Participants
|
|
Age, Continuous
|
58.53 years
STANDARD_DEVIATION 15.27 • n=5 Participants
|
64.02 years
STANDARD_DEVIATION 10.4 • n=7 Participants
|
55.68 years
STANDARD_DEVIATION 10.17 • n=5 Participants
|
64.12 years
STANDARD_DEVIATION 11.73 • n=4 Participants
|
55.79 years
STANDARD_DEVIATION 8.89 • n=21 Participants
|
59.6 years
STANDARD_DEVIATION 9.5 • n=8 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
14 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
9 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
47 Participants
n=8 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
7 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
9 Participants
n=4 Participants
|
20 Participants
n=21 Participants
|
59 Participants
n=8 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Asian
|
3 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
5 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
14 Participants
n=8 Participants
|
|
Race (NIH/OMB)
White
|
2 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
20 Participants
n=21 Participants
|
41 Participants
n=8 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
|
Region of Enrollment
United States
|
8 participants
n=5 Participants
|
12 participants
n=7 Participants
|
12 participants
n=5 Participants
|
9 participants
n=4 Participants
|
20 participants
n=21 Participants
|
61 participants
n=8 Participants
|
|
Previous Therapy
Any surgical resection
|
3 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
19 Participants
n=8 Participants
|
|
Previous Therapy
Any TACE
|
2 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
9 Participants
n=8 Participants
|
|
Previous Therapy
Any chemotherapy
|
8 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
9 Participants
n=4 Participants
|
20 Participants
n=21 Participants
|
60 Participants
n=8 Participants
|
|
Previous Therapy
Any radiation therapy
|
3 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
9 Participants
n=8 Participants
|
|
Previous Therapy
Misc. therapy - Y90
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
|
Previous Therapy
Misc. therapy - Hyperthermia
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1; 49 months and 26 days for 2/Arm A2; 1 month and 26 days for 3/Arm B; 30 months and 20 days for 5/Arm D; and 34 months and 25 days for 6/Arm E.Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Outcome measures
| Measure |
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
n=8 Participants
Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 3.5 mg/kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
2/Arm A2 - Tremelimumab + RFA or TACE
n=12 Participants
Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
3/Arm B - Tremelimumab + TACE
n=12 Participants
Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
5/Arm D - Tremelimumab + Cryoablation
n=9 Participants
Tremelimumab + Cryoablation
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Cryoablation: Performed on Day 36
|
6/Arm E - Tremelimumab + RFA
n=20 Participants
Tremelimumab + Radiofrequency Ablation (RFA)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
|
|---|---|---|---|---|---|
|
Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution
|
8 Participants
|
12 Participants
|
12 Participants
|
9 Participants
|
20 Participants
|
SECONDARY outcome
Timeframe: Start of study, baseline target lesions until disease progression occurs with 20% increase of target lesions or appearance of new lesions, up to 13.1 monthsBest response was assessed by the combined Response Evaluation Criteria in Solid Tumors (RECIST and the Modified Immune-Related Response Criteria (irRC). Complete Response (CR) is disappearance of all target lesions. Any patjhological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if it is the smallest on study). The appearance of one or more lesions is also considered progressions.
Outcome measures
| Measure |
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
n=8 Participants
Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 3.5 mg/kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
2/Arm A2 - Tremelimumab + RFA or TACE
n=12 Participants
Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
3/Arm B - Tremelimumab + TACE
n=12 Participants
Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
5/Arm D - Tremelimumab + Cryoablation
n=9 Participants
Tremelimumab + Cryoablation
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Cryoablation: Performed on Day 36
|
6/Arm E - Tremelimumab + RFA
n=20 Participants
Tremelimumab + Radiofrequency Ablation (RFA)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
|
|---|---|---|---|---|---|
|
Number of Participants With Best Response
Complete Response
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Best Response
Partial Response
|
1 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
|
Number of Participants With Best Response
Stable Disease
|
3 Participants
|
5 Participants
|
4 Participants
|
3 Participants
|
5 Participants
|
|
Number of Participants With Best Response
Progressive Disease
|
1 Participants
|
3 Participants
|
4 Participants
|
3 Participants
|
11 Participants
|
|
Number of Participants With Best Response
Not Evaluable
|
3 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: Progression free survival is time patients were off treatment until death. For all cohorts progression free survival ranged from 3.4 months to 8.6 monthsProgression free survival is defined as the amount of time a subject survives without disease progression after treatment. Progression is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if it is the smallest on study). The appearance of one or more lesions is also considered progressions.
Outcome measures
| Measure |
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
n=8 Participants
Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 3.5 mg/kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
2/Arm A2 - Tremelimumab + RFA or TACE
n=12 Participants
Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
3/Arm B - Tremelimumab + TACE
n=12 Participants
Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
5/Arm D - Tremelimumab + Cryoablation
n=9 Participants
Tremelimumab + Cryoablation
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Cryoablation: Performed on Day 36
|
6/Arm E - Tremelimumab + RFA
n=20 Participants
Tremelimumab + Radiofrequency Ablation (RFA)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
|
|---|---|---|---|---|---|
|
Progression Free Survival (PFS)
|
6.4 Months
Interval 0.8 to 12.0
|
7.5 Months
Interval 5.6 to 9.3
|
7.7 Months
Interval 5.8 to 9.5
|
8.6 Months
Interval 2.8 to 15.5
|
3.4 Months
Interval 2.5 to 5.2
|
SECONDARY outcome
Timeframe: From the time of initial treatment consent until date of death for each patient. Overall survival ranged from 6 months to 13.1 months.Overall survival is defined as the amount of time a subject survives after therapy.
Outcome measures
| Measure |
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
n=8 Participants
Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 3.5 mg/kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
2/Arm A2 - Tremelimumab + RFA or TACE
n=12 Participants
Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
3/Arm B - Tremelimumab + TACE
n=12 Participants
Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
5/Arm D - Tremelimumab + Cryoablation
n=9 Participants
Tremelimumab + Cryoablation
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Cryoablation: Performed on Day 36
|
6/Arm E - Tremelimumab + RFA
n=20 Participants
Tremelimumab + Radiofrequency Ablation (RFA)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
|
|---|---|---|---|---|---|
|
Overall Survival
|
10.5 Months
Interval 5.2 to 15.7
|
8.4 Months
Interval 6.5 to 10.3
|
13.1 Months
Interval 11.3 to 15.0
|
13.1 Months
Interval 6.3 to 19.9
|
6 Months
Interval 3.8 to 8.8
|
Adverse Events
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
Serious events: 5 serious events
Other events: 8 other events
Deaths: 8 deaths
2/Arm A2 -Tremelimumab + RFA or TACE
Serious events: 1 serious events
Other events: 12 other events
Deaths: 1 deaths
3/Arm B - Tremelimumab + TACE
Serious events: 7 serious events
Other events: 12 other events
Deaths: 8 deaths
5/Arm D - Tremelimumab + Cryoablation
Serious events: 3 serious events
Other events: 9 other events
Deaths: 6 deaths
6/Arm E - Tremelimumab + RFA
Serious events: 7 serious events
Other events: 20 other events
Deaths: 17 deaths
Serious adverse events
| Measure |
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
n=8 participants at risk
Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 3.5 mg/kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
2/Arm A2 -Tremelimumab + RFA or TACE
n=12 participants at risk
Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
3/Arm B - Tremelimumab + TACE
n=12 participants at risk
Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
5/Arm D - Tremelimumab + Cryoablation
n=9 participants at risk
Tremelimumab + Cryoablation
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Cryoablation: Performed on Day 36
|
6/Arm E - Tremelimumab + RFA
n=20 participants at risk
Tremelimumab + Radiofrequency Ablation (RFA)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
|
|---|---|---|---|---|---|
|
Immune system disorders
Anaphylaxis
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Aspartate aminotransferase increased
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Gastrointestinal disorders - Other, Gastroenteritis
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Vascular disorders
Hypotension
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, HCC
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Non-cardiac chest pain
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Diarrhea
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Gastrointestinal disorders - Other, Inguinal hernia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Vascular disorders
Hematoma
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Vascular disorders
Hypertension
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Intra-abdominal hemorrhage
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Lung infection
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Muscle weakness left-sided
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Seizure
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Infections and infestations - Other, C. Diff.
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Muscle weakness lower limb
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Nervous system disorders - Other, Blackout
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Blood and lymphatic system disorders
Anemia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Chills
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Fever
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Meningitis
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural hemorrhage
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Sepsis
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Soft tissue infection
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Stroke
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
Other adverse events
| Measure |
Pilot 1/Arm A1-Tremelimumab + RFA or TACE
n=8 participants at risk
Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 3.5 mg/kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
2/Arm A2 -Tremelimumab + RFA or TACE
n=12 participants at risk
Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
3/Arm B - Tremelimumab + TACE
n=12 participants at risk
Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
TACE: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
|
5/Arm D - Tremelimumab + Cryoablation
n=9 participants at risk
Tremelimumab + Cryoablation
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Cryoablation: Performed on Day 36
|
6/Arm E - Tremelimumab + RFA
n=20 participants at risk
Tremelimumab + Radiofrequency Ablation (RFA)
Tremelimumab: 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA: Performed on Day 36
|
|---|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal distension
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
37.5%
3/8 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
25.0%
3/12 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
20.0%
4/20 • Number of events 6 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Abdominal pain
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 19 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
44.4%
4/9 • Number of events 8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
60.0%
12/20 • Number of events 21 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Activated partial thromboplastin time prolonged
|
50.0%
4/8 • Number of events 15 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
83.3%
10/12 • Number of events 11 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
75.0%
9/12 • Number of events 20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
44.4%
4/9 • Number of events 6 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
70.0%
14/20 • Number of events 26 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Psychiatric disorders
Agitation
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Alanine aminotransferase increased
|
87.5%
7/8 • Number of events 33 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
83.3%
10/12 • Number of events 33 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
77.8%
7/9 • Number of events 16 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
40.0%
8/20 • Number of events 16 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Alkaline phosphatase increased
|
87.5%
7/8 • Number of events 27 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
83.3%
10/12 • Number of events 43 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
55.6%
5/9 • Number of events 12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
65.0%
13/20 • Number of events 25 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Blood and lymphatic system disorders
Anemia
|
100.0%
8/8 • Number of events 31 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
100.0%
12/12 • Number of events 17 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
91.7%
11/12 • Number of events 68 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
100.0%
9/9 • Number of events 31 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
100.0%
20/20 • Number of events 73 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Anorexia
|
25.0%
2/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 11 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
41.7%
5/12 • Number of events 9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
40.0%
8/20 • Number of events 11 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Ascites
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
25.0%
3/12 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
35.0%
7/20 • Number of events 10 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Aspartate aminotransferase increased
|
100.0%
8/8 • Number of events 46 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
83.3%
10/12 • Number of events 55 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
88.9%
8/9 • Number of events 25 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
65.0%
13/20 • Number of events 39 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Hepatobiliary disorders
Bile duct stenosis
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Bloating
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
20.0%
4/20 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Blood bilirubin increased
|
75.0%
6/8 • Number of events 24 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
66.7%
8/12 • Number of events 35 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
44.4%
4/9 • Number of events 14 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
35.0%
7/20 • Number of events 21 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
CPK increased
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Chills
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Psychiatric disorders
Confusion
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Constipation
|
37.5%
3/8 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
66.7%
8/12 • Number of events 12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
20.0%
4/20 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
25.0%
2/8 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
41.7%
5/12 • Number of events 8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
25.0%
5/20 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Creatinine increased
|
37.5%
3/8 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
44.4%
4/9 • Number of events 17 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
35.0%
7/20 • Number of events 15 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
25.0%
3/12 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
44.4%
4/9 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Dental caries
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Diarrhea
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 6 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
45.0%
9/20 • Number of events 16 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Dizziness
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
55.6%
5/9 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
15.0%
3/20 • Number of events 6 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Dyspepsia
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Dysphagia
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
25.0%
2/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
33.3%
3/9 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
15.0%
3/20 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Esophageal varices hemorrhage
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Eye disorders
Eyelid function disorder
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Fatigue
|
37.5%
3/8 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
66.7%
8/12 • Number of events 13 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
60.0%
12/20 • Number of events 18 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Fever
|
37.5%
3/8 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
58.3%
7/12 • Number of events 9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
55.0%
11/20 • Number of events 20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Fibrinogen decreased
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Flu like symptoms
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Gastrointestinal disorders - Other, Dry throat
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
25.0%
2/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Ear and labyrinth disorders
Hearing impaired
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Vascular disorders
Hematoma
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Renal and urinary disorders
Hematuria
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Renal and urinary disorders
Hemoglobinuria
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypernatremia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Vascular disorders
Hypertension
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hyperuricemia
|
25.0%
2/8 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
87.5%
7/8 • Number of events 27 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
83.3%
10/12 • Number of events 44 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
91.7%
11/12 • Number of events 74 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
77.8%
7/9 • Number of events 29 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
80.0%
16/20 • Number of events 60 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
25.0%
3/12 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
33.3%
3/9 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
30.0%
6/20 • Number of events 10 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypokalemia
|
25.0%
2/8 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
41.7%
5/12 • Number of events 14 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
66.7%
6/9 • Number of events 16 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
40.0%
8/20 • Number of events 15 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
25.0%
2/8 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
25.0%
3/12 • Number of events 17 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
35.0%
7/20 • Number of events 11 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hyponatremia
|
100.0%
8/8 • Number of events 19 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
100.0%
12/12 • Number of events 40 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
100.0%
12/12 • Number of events 44 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
66.7%
6/9 • Number of events 25 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
60.0%
12/20 • Number of events 31 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
37.5%
3/8 • Number of events 6 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
75.0%
9/12 • Number of events 38 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
55.6%
5/9 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
40.0%
8/20 • Number of events 21 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Vascular disorders
Hypotension
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Infections and infestations - Other, Oral thrush
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Psychiatric disorders
Insomnia
|
25.0%
2/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
58.3%
7/12 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
15.0%
3/20 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Mucositis oral
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Muscle weakness upper limb
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, HCC
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Neuralgia
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Paresthesia
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Postnasal drip
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
50.0%
4/8 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
25.0%
3/12 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
33.3%
3/9 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
40.0%
8/20 • Number of events 14 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Rash acneiform
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
62.5%
5/8 • Number of events 11 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
41.7%
5/12 • Number of events 8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
45.0%
9/20 • Number of events 11 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Renal and urinary disorders
Renal and urinary disorders - Other, Dysuria
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders - Other, shortness of breath
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders - Other, upper respiratory infection
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Serum amylase increased
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 27 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
33.3%
3/9 • Number of events 15 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Cardiac disorders
Sinus tachycardia
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, mouth ulcers
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
|
25.0%
2/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Renal and urinary disorders
Urinary frequency
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Vomiting
|
37.5%
3/8 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
25.0%
3/12 • Number of events 8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
20.0%
4/20 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Weight loss
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
White blood cell decreased
|
50.0%
4/8 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Injury, poisoning and procedural complications
Wound complication
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Cardiac disorders
Atrial flutter
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Eye disorders
Blurred vision
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Bronchial infection
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Psychiatric disorders
Depression
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Eye disorders
Dry eye
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Edema trunk
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Vascular disorders
Flushing
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Gastrointestinal disorders - Other, gastrointestinal disorders - Other, cramping
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Hoarseness: voice changes
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Psychiatric disorders
Hypersomnia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Lung infection
|
12.5%
1/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Myalgia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysesthesia syndrome
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Cardiac disorders
Palpitations
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Papulopustular rash
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Peripheral motor neuropathy
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders - Other, Pneumonia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, skin discoloration
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, skin peeling - bil. Hands
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Skin infection
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Injury, poisoning and procedural complications
Burn
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Cardiac disorders
Cardiac disorders - Other, atrial fib with bradycardia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Chest wall pain
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Colonic hemorrhage
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
41.7%
5/12 • Number of events 8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Infections and infestations - Other, Infection - E.coli
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Infusion related reaction
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Lipase increased
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 18 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Muscle weakness lower limb
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Psychiatric disorders
Restlessness
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, blisters on abdominal area
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, various scabs
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor pain
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/20 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Concentration impairment
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Psychiatric disorders
Delayed orgasm
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Dysphasia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Edema limbs
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
33.3%
3/9 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
30.0%
6/20 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Eye infection
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
General disorders and administration site conditions - Other, neuro-gait abnormalities
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Headache
|
25.0%
2/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Hemorrhoids
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
62.5%
5/8 • Number of events 6 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
41.7%
5/12 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
33.3%
3/9 • Number of events 6 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
40.0%
8/20 • Number of events 32 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
25.0%
2/8 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 13 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypermagnesemia
|
25.0%
2/8 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Infections and infestations - Other, C. Diff infection
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Infections and infestations - Other, Infection-GI other, liver infection
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Lymphocyte count decreased
|
87.5%
7/8 • Number of events 32 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 31 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
91.7%
11/12 • Number of events 68 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
77.8%
7/9 • Number of events 23 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
85.0%
17/20 • Number of events 63 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Lymphocyte count increased
|
12.5%
1/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Malaise
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Nausea
|
37.5%
3/8 • Number of events 5 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
50.0%
6/12 • Number of events 16 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
66.7%
8/12 • Number of events 15 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
22.2%
2/9 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
20.0%
4/20 • Number of events 6 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Neutrophil count decreased
|
12.5%
1/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
16.7%
2/12 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 14 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
15.0%
3/20 • Number of events 7 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Musculoskeletal and connective tissue disorders
Non-cardiac chest pain
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
General disorders
Pain
|
62.5%
5/8 • Number of events 11 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
33.3%
4/12 • Number of events 17 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
66.7%
8/12 • Number of events 34 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
66.7%
6/9 • Number of events 10 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
65.0%
13/20 • Number of events 26 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Investigations
Platelet count decreased
|
62.5%
5/8 • Number of events 25 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
25.0%
3/12 • Number of events 12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
41.7%
5/12 • Number of events 22 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
55.6%
5/9 • Number of events 15 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
45.0%
9/20 • Number of events 22 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
25.0%
2/8 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
8.3%
1/12 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Rectal hemorrhage
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, itching
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, lymph node swelling
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, night sweats
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Gastrointestinal disorders
Sore throat
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
11.1%
1/9 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Respiratory, thoracic and mediastinal disorders
Upper respiratory infection
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
20.0%
4/20 • Number of events 4 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Infections and infestations
Urinary tract infection
|
12.5%
1/8 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 2 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
5.0%
1/20 • Number of events 1 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
|
Metabolism and nutrition disorders
Weight loss
|
0.00%
0/8 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/12 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
0.00%
0/9 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
10.0%
2/20 • Number of events 3 • Date treatment consent signed to date off study, approximately 44 months and 5 days for 1/Arm A1-Tremelimumab + RFA or TACE; 49 months and 26 days for 2/Arm A2-MTD of Tremelimumab + RFA or TACE; 1 month and 26 days for 3/Arm B-MTD of Tremelimumab + TACE; 30 months and 20 days for 5/Arm D-MTD of Tremelimumab + Cryoablation; and 34 months and 25 days for 6/Arm E-MTD of Tremelimumab + RFA.
All deaths in the mortality module are attributable to progressive disease (all deaths that occurred are reported).
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place